Table 1 Characteristics of Alzheimer’s disease patients according the presence of microbleeds
From: Clinical impact of microbleeds in patients with Alzheimer’s disease
Number of patients (% of patients) | ||||
|---|---|---|---|---|
Total cohort (n = 98) | No Microbleeds (n = 50) | Microbleeds (n = 48) | p value No microbleeds vs microbleeds | |
Female | 57 (58.2) | 34 (68.0) | 23 (47.9) | 0.044 |
Age, mean (SD), y | 75.4 (5.45) | 74.4 (5.69) | 76.4 (5.06) | 0.475 |
MMSE score, mean (SD) | 23. 90 (3.45) | 24.17 (3.66) | 23.87 (2.92) | 0.074 |
Hypertension | 53 (54.1) | 26 (52.0) | 27 (56.3) | 0.673 |
Hypercholesterolemia | 43 (42.14) | 25 (50.0) | 17 (35.4) | 0.145 |
Diabetes mellitus | 24 (24.5) | 11 (22.0%) | 13 (27.1) | 0.559 |
Current smoking | 3 (2.94) | 0 (0) | 3 (6.3) | 0.175 |
Blood pressure, mean (SD), mm/Hg | ||||
Systolic | 140.06 (19.13) | 139.69 (19.55) | 140.32 (18.71) | 0.439 |
Diastolic | 82.55 (10.13) | 82.04 (9.89) | 82.71 (10.50) | 0.764 |
BMI, mean (SD) | 27.56 (3.64) | 27.66 (3.75) | 27.51 (3.62) | 0.858 |
Lacune presence | ||||
WMH presence (Fazekas ≥2) | 32 (31.36) | 11 (22.0) | 21 (43.8) | 0.022 |
Antiplatelet drugs | 22 (21.56) | 9 (18.8) | 11 (23.4) | 0.578 |
CSF, mean (SD), pg/mL | ||||
Aβ42 | 581.43 (257.82) | 594.26 (243.9) | 526.88 (209.62) | 0.673 |
Total tau | 510.35 (268.95) | 500.34 (246.52) | 527.02 (295.61) | 0.317 |
pTau | 83.30 (52.50) | 84.07 (64.41) | 83.33 (38.23) | 0.736 |
ApoE ε4 | 44 (45.8) | 24 (51.0) | 20 (48.8) | 0.314 |